

Pharmacotherapy for Opioid Use Disorder (POD)

By working together, we can improve health outcomes for your patients, our members. The Healthcare Effectiveness Data and Information Set (HEDIS®) helps us measure many aspects of performance. This tip sheet provides key details of the HEDIS measure for pharmacotherapy for opioid use disorder.

What Is the Measure?

The measure monitors members age 16 and older with a diagnosis of opioid use disorder (OUD) and a new OUD pharmacotherapy event that lasted at least 180 days.

Note:

- Members can have multiple treatment period start dates during the measurement year.
- Pharmacy and medical claims qualify the member for the measure and determine compliance.
- Methadone **is not** included because it is indicative of treatment for pain rather than OUD.

Exclusions

- Any acute or nonacute inpatient stay of eight or more days during the treatment period
- Members in hospice or using hospice services during the measurement year
- Members who died during the measurement year

Exclusions Codes

Hospice Encounter

HPCPS: G9473–G9479, Q5003–Q5008, Q5010, S9126, T2042–T2046

Hospice Intervention

CPT: 99377–99378

HPCPS: G0182

Codes for Reporting Opioid Use

Description

Opioid Use and Dependence

ICD-10

F11.10, F11.120–F11.122, F11.129, F11.13–F11.14, F11.150–F11.151, F11.159, F11.181–F11.182, F11.188, F11.19–F11.20, F11.220–F11.222, F11.229, F11.23–F11.24, F11.250–F11.251, F11.259, F11.281–F11.282, F11.288, F11.29

Continued next page

All summaries of the measures contained herein are reproduced with permission from HEDIS Volume 1: Technical Specifications for Health Plans by the National Committee for Quality Assurance (NCQA). HEDIS® is a registered trademark of the NCQA. Please see the final page of this document for the full copyright citation.

Florida Blue is an independent licensee of the Blue Cross and Blue Shield Association.
2113560 0124R

Opioid Use Disorder Treatment Medications

Description	Prescription
Antagonist	Naltrexone (oral)
Antagonist	Naltrexone (injectable)
Partial agonist	Buprenorphine (sublingual tablet)
Partial agonist	Buprenorphine (injection)
Partial agonist	Buprenorphine (implant)
Partial agonist	Buprenorphine/ naloxone (sublingual tablet, buccal film, sublingual film)
Agonist	Methadone (oral)

Content reproduced with permission from HEDIS® MY2024, Volume 1: Technical Specifications for Health Plans by the National Committee for Quality Assurance (NCQA). HEDIS measures and specifications are not clinical guidelines and do not establish a standard of medical care. NCQA makes no representations, warranties, or endorsement about the quality of any organization or physician that uses or reports performance measures and NCQA has no liability to anyone who relies on such measures or specifications. Limited proprietary coding sets are contained in the specifications for convenience, and users should obtain all necessary licenses from the owners of the code sets. NCQA disclaims all liability for use or accuracy of any coding contained in the specifications. To purchase copies of the publication, including the full measures and specifications, visit [NCQA.org/Publications](https://www.ncqa.org/Publications).